AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

D2 Agonist - Pipeline Insight, 2019 - ResearchAndMarkets.com

February 19, 2019

DUBLIN--(BUSINESS WIRE)--Feb 19, 2019--The “D2 Agonist - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

D2 Agonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across D2 Agonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

Reasons to Buy

Topics Covered

1. Report Introduction

2. D2 Agonist - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. D2 Agonist Pipeline Products in Clinical Stages

6. D2 Agonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/d96q2l/d2_agonist?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190219005883/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/19/2019 01:59 PM/DISC: 02/19/2019 01:59 PM

http://www.businesswire.com/news/home/20190219005883/en